The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INBX | +99.49% | N/A | N/A | +126% |
| S&P | +14.5% | +93.32% | +14.09% | +27% |
Inhibrx Biosciences, Inc. operates as an American clinical-stage biotechnology company for biologic therapeutic candidates. The private company is based in DE.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.30M | 1200.0% |
| Gross Profit | $0.64M | 270.1% |
| Gross Margin | 49.08% | 424.1% |
| Market Cap | $206.57M | 0.7% |
| Market Cap / Employee | $1.28M | 0.0% |
| Employees | 161 | 0.0% |
| Net Income | -$28.65M | -101.5% |
| EBITDA | -$26.73M | 83.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $186.57M | -17.8% |
| Accounts Receivable | $0.24M | -45.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $104.62M | 0.0% |
| Short Term Debt | $2.17M | -0.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -69.58% | 0.0% |
| Return On Invested Capital | 351.55% | 426.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.95M | 48.9% |
| Operating Free Cash Flow | -$29.95M | 47.8% |
| Metric | Q4 2024 | Q1 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 0.13 | 0.12 | - | ||
| Price to Book | 1.03 | 1.25 | 1.52 | 2.19 | -87.66% |
| Price to Sales | 1114.64 | 1081.99 | 157.66 | - | |
| Price to Tangible Book Value | 1.03 | 1.25 | 1.52 | 2.19 | -87.66% |
| Enterprise Value to EBITDA | -0.70 | -1.59 | -2.52 | -5.27 | -4424.13% |
| Return on Equity | 3250.6% | -113.7% | - | ||
| Total Debt | $1.84M | $8.05M | $106.53M | $106.79M | 4818.89% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
